Repositioning Candidate Details
| Candidate ID: | R0595 |
| Source ID: | DB03849 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Cilomilast |
| Synonyms: | Ariflo; Cilomilast; cis-4-cyano-4-(3-(cyclopentyloxy)-4-methoxyphenyl)cyclohexanecarboxylic acid |
| Molecular Formula: | C20H25NO4 |
| SMILES: | COC1=C(OC2CCCC2)C=C(C=C1)[C@]1(CC[C@@H](CC1)C(O)=O)C#N |
| Structure: |
|
| DrugBank Description: | Cilomilast (Ariflo, SB-207,499) is a drug which was developed for the treatment of respiratory disorders such as asthma and Chronic Obstructive Pulmonary Disease (COPD). It is orally active and acts as a selective Phosphodiesterase-4 inhibitor. Following four clinical trials, the drug proved to be effective in treating COPD, however it has never been marketed due to a poor side effect profile. |
| CAS Number: | 153259-65-5 |
| Molecular Weight: | 343.4168 |
| DrugBank Indication: | Investigated for use/treatment in chronic obstructive pulmonary disease (COPD). |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | Cilomilast shows high selectivity for cAMP-specific PDE4, an isoenzyme that predominates in pro-inflammatory and immune cells and that is 10-fold more selective for PDE4D than for PDE4A, -B or -C. In vitro, cilomilast suppresses the activity of several pro-inflammatory and immune cells that have been implicated in the pathogenesis of asthma and COPD. Moreover, it is highly active in animal models of these diseases. Cilomilast has been shown to exert potent anti-inflammatory effects both in vitro and in vivo. |
| Targets: | cAMP-specific 3',5'-cyclic phosphodiesterase 4D inhibitor; cAMP-specific 3',5'-cyclic phosphodiesterase 4B inhibitor |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|